All In Biotech

Drug Trial Radar · NCT02208063

A Phase 3 Telavancin Staphylococcus Aureus (S. Aureus) Bacteremia Trial

A Phase 3 Multicenter, Randomized, Open-label, Clinical Trial of Telavancin Versus Standard Intravenous Therapy in the Treatment of Subjects With Staphylococcus Aureus Bacteremia Including Infective Endocarditis

Last checked: Nov 20, 2026Latest source record: Feb 17, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 121 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

121

Actual

Start

Dec 2014

Primary completion

Apr 12, 2018

Study completion Apr 12, 2018

Sponsor

Lead sponsor
Cumberland PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Aug 4, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, open-label, noninferiority trial of telavancin versus standard IV therapy control (e.g., vancomycin, daptomycin, anti-staphylococcal penicillin (PCN), or cefazolin) in the treatment of subjects with complicated Staphylococcus aureus (S. aureus) bacteremia and SA right-sided infective endocarditis (SA-RIE).

Conditions

  • Bacteremia

Interventions

  • TelavancinDrug

  • VancomycinDrug

  • DaptomycinDrug

  • Synthetic penicillinDrug

  • CefazolinDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With a Clinical Outcome of Cure at Test of Cure (TOC)Time frame: Up to 8 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Remington-Davis Clinical Research

    Columbus, Ohio

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.